Memory B cells are long-lived antigen-experienced B cells that typically express high-affinity B cell receptor (BCR), rapidly expand and differentiate into plasma cells upon antigen re-challenge^[@R1],[@R2]^. While IgM memory B cells have specialized functions^[@R3]^, many antigen-primed B cells switch to non-IgM isotypes under the antigen-specific regulation of follicular helper T cells^[@R4]^. Furthermore, non-IgM classes of membrane-bound antibody have differing abilities to transduce signals through their BCR based on the expressed constant region^[@R5],[@R6]^. However, little is known about the molecular signals required for class-switched memory B cell survival, activation or differentiation. Several studies have delineated how cytokines differentially affect transcriptional programs in naïve B cells that culminate in class switch recombination^[@R7],[@R8]^. Interleukin 4 (IL-4) and interferon-γ (IFN-γ) reciprocally regulate IgG1 and IgG2a class switch^[@R7]^, while the capacity to express TGFβR2 in naive B cells is required for IgA switch^[@R9]^. However, it remains to be studied whether programmatic differences initiated at the time of class-switch extend into memory B cell compartments to control longevity, cell fate and memory B cell function in an antibody class-specific manner.

Differentiation of immune effector cells relies heavily on transcription factors belonging to three families: T-box, GATA, and Retinoic acid receptor-related Orphan Receptors (RORs)^[@R10]^. Members of all three families share the ability to directly interact with chromatin remodeling machinery to transactivate or repress gene targets in a cell context-dependent manner. Transcriptional regulators from each family induce molecular programs known to specify immune cell lineages into functional subsets^[@R11]--[@R13]^. T-bet, a member of the T-box family, plays a critical role inducing IFN-γ production by T~H~1, natural killer (NK), and CD8^+^ cells to regulate antiviral immunity^[@R12]^. T-bet expression by naive B cells is sufficient to promote IgG2a class switch and is required for IFN-γ induced production of IgG2a antibody *in vivo*^[@R14],[@R15]^. In contrast, GATA family members are expressed by T~H~2 cells, basophils and mast cells, crucial to IL-4 production and immunity against helminthes^[@R13]^. While ROR family members are less characterized, RORγt and RORα are found in T~H~17 cells^[@R16]^ and known to be involved in mucosal immunity against extracellular bacteria^[@R11]^. While factors belonging to these families have been well characterized in several immune subsets, their roles in memory B cell development and the regulation of memory B cell function remain unknown.

Here, we focus on IgG2a^+^ and IgA^+^ memory B cells and provide evidence for the divergent programming of memory B cell function by major transcriptional regulators T-bet and RORα. Temporal deletion of T-bet in IgG2a^+^ memory B cells established a central and selective role for this regulator in IgG2a^+^ memory B cell survival and antigen responsiveness *in vivo*. Differential expression of cytokine receptors, integrins and RORα highlighted the specialized development and unique properties of IgA memory B cells. Importantly, a role for both T-bet and RORα in persistent BCR transcription indicated dynamic and ongoing class-specific requirements for each of these factors in IgG2a^+^ and IgA^+^ memory B cells, respectively. Taken together, we propose that expression of non-IgM antibody signifies a transcriptionally regulated commitment event across sub-specialized, class-specific memory B cells.

RESULTS {#S1}
=======

IgG2a memory formation requires T-bet in B cells {#S2}
------------------------------------------------

To look for the existence of class-specific transcriptional programs, we first focused on IgG2a^+^ memory B cells given evidence that B cell intrinsic expression of T-bet is sufficient to induce IgG2a germline transcripts^[@R15]^. Furthermore, IFN-γ provided by transferred OT-1 transgenic CD8^+^ T cells skewed B cells towards IgG2a class-switch *in vivo* in ways dependent on non-T cell T-bet expression^[@R14]^. To address the B cell intrinsic requirement for T-bet in IgG2a class switch more directly and in polyclonal animals, we used animals with a germline *Tbx21* deletion^[@R17]^. These animals display defects in multiple cell types^[@R12]^ including defects in serum IgG antibody^[@R15]^. Consistent with these antibody results, analysis of the *Tbx21*^−/−^ animals revealed significant decreases in IgG3, IgG2a and IgG2b class-switched (IgM^−^IgD^−^) CD38^hi^ B cells (also CD19^+^B220^+^CD138^−^) compared to intact IgG1^+^ B cells ([Fig. 1a](#F1){ref-type="fig"} & [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Thus, development of these putative memory B cell subsets was compromised in the absence of T-bet with no direct or indirect requirement for T-bet in IgG1 memory development.

To provide *Tbx21*^−/−^ B cells a source of wild-type polyclonal T cell help, we generated *Rag1*^−/−^ mixed peripheral chimeras containing equal numbers of wild-type and *Tbx21*^−/−^ spleen cells ([Fig. 1b](#F1){ref-type="fig"}). Upon hapten-protein immunization (nitrophenylacetyl-keyhole limpet hemocyanin; NP-KLH), both wild-type and *Tbx21*^−/−^ B cell compartments produced robust class-switched NP-specific B cell responses ([Fig. 1c](#F1){ref-type="fig"}). Strikingly, there was \>95% reduction in the antigen-specific IgG2a^+^ B cell response ([Fig. 1d](#F1){ref-type="fig"}) that extended across antigen-specific germinal center (CD38^lo^), memory B (CD38^hi^) cell ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}) and plasma cell (CD138^hi^) compartments ([Fig. 1e](#F1){ref-type="fig"}) in the B cell-specific absence of T-bet. In contrast, slightly higher IgG1^+^ NP-specific B cell responses were induced in both donor populations ([Fig. 1d](#F1){ref-type="fig"}) with similar distribution into germinal center, memory B cell ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}) and plasma cells compartments ([Fig. 1e](#F1){ref-type="fig"}). No defects were found in IgG3 and IgG2b NP-specific B cell compartments in the absence of T-bet ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). Furthermore, total class-switched B cells, that would contain the KLH-specific response and polyclonal reactivities in the peripheral chimeras, displayed a similar selective defect in IgG2a with concentrations of IgG1, IgG3 and IgG2b B cell compartments equivalent to wild-type ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Therefore, B cell intrinsic expression of T-bet is required selectively for IgG2a class switch and/or survival of IgG2a^+^ B cells after class switch *in vivo*.

IgG2a memory B cell survival and function requires T-bet {#S3}
--------------------------------------------------------

To enable analysis of T-bet expression in IgG2a^+^ B cells after class-switch, we crossed *Tbx21*^F/F^ mice^[@R18]^ to C57BL/6 mice with tamoxifen-inducible Cre in the ubiquitously expressed *Rosa26* locus (*Rosa26*-CreER^T2^). Treatment of intact CreER^T2^ *Tbx21*^F/F^ mice with 4-hydroxy-tamoxifen (4-OHT) induced the loss of T-bet protein in \>50% of T-bet expressing splenocytes ([Fig. 2a](#F2){ref-type="fig"}). There were similar reductions in IgG2a^+^ B cells in treated animals with no change in numbers of IgG1^+^ B cells. Importantly, all remaining IgG2a^+^ B cells expressed T-bet protein ([Fig. 2b](#F2){ref-type="fig"}) at levels equivalent to treated Cre-ER^T2^ *Tbx21*^+/+^ animals (not shown). Thus, ablation of *Tbx21 in vivo* led to significant loss of IgG2a^+^ memory B cells over 4 days with no exogenous BCR stimulus.

As temporal deletion with 4-OHT *in vivo* targets all cells, it was important to determine whether B cell-specific loss of T-bet had caused the selective IgG2a deficit. In the next strategy, we induced an NP-specific B cell response in the CreER^T2^ *Tbx21*^F/F^ and CreER^T2^ *Tbx21*^+/+^ donor mice that contained antigen-specific B220^hi^ IgG1^+^ and IgG2a^+^ compartments ([Fig. 2c,d](#F2){ref-type="fig"} & [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). Splenocytes from both of these donors were treated *in vitro* with 4-OHT for 1 h. This treatment excised \>90% of the *Tbx21*^F/F^ allele ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}) and controls for toxicity of treatment in wild-type cells. Both sets of treated cells were transferred into separate *Rag1*^−/−^ recipients together with T-bet sufficient splenocytes from NP-KLH immunized wild-type congenic mice. The mixed peripheral chimeras were then challenged 24 h later with soluble antigen without adjuvant (unable to induce a primary NP-specific response; not shown), to promote a secondary NP-specific B cell response in recipients. Both *Tbx21*^F/F^ and *Tbx21*^+/+^ 4-OHT treated sources of NP-specific B cells induced secondary responses to soluble antigen with equivalent NP-binding CD138^−^B220^+^ B cells and plasma cells ([Fig. 2e](#F2){ref-type="fig"}). However, the NP-specific IgG2a^+^ recall response required T-bet with \<5% of *Tbx21*^F/F^ B cells responding after 4-OHT treatment compared to wild-type B cells ([Fig. 2f](#F2){ref-type="fig"}). The NP-specific IgG1 response remained intact and emerged to equivalent extent as seen in the absence of T-bet ([Fig. 2f](#F2){ref-type="fig"}). The same trends were seen across the IgG2a and IgG1 plasma cell compartment ([Fig. 2f](#F2){ref-type="fig"}). Mixed chimeras were constructed 6 months after initial priming of donor animals and displayed the same selective loss of IgG2a^+^ NP-specific cells upon transfer and immunization ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). Thus, IgG2a^+^ memory B cells selectively require B cell-intrinsic T-bet expression to respond effectively to antigen re-challenge *in vivo*.

T-bet persists during IgG2a memory B cell development {#S4}
-----------------------------------------------------

Next, we assessed changes in *Tbx21* expression over the course of a primary and memory response in NP-KLH immunized animals^[@R19],[@R20]^ ([Fig. 3a](#F3){ref-type="fig"}). Differential CD138, B220 and CD38 expression on class-switched (IgM^−^IgD^−^) antigen-binding (NP^+^) CD19^+^ B cells provided direct access to IgG2a^+^ B cells ([Fig. 3b](#F3){ref-type="fig"}). We used Bcl-6 (ref.^[@R21]^) and Blimp-1 (ref.^[@R22]^) expression together with antibody isotype and phenotypic markers to further distinguish pre-GC (day 7; B220^hi^CD38^hi^ Bcl6^lo^), germinal center (day 7, 14 B220^hi^CD38^lo^ Bcl6^hi^), memory (day 14 primary, day 5 and 14 secondary, B220^hi^CD38^hi^ Bcl6^lo^) and plasma cell (CD138^hi^, Blimp-1^hi^) stages of antigen-specific IgG2a^+^ memory B cell development ([Fig. 3c](#F3){ref-type="fig"}). As anticipated, T-bet was abundantly expressed in primary antigen-responsive IgG2a^+^ B cells before entry into germinal centers, then decreased significantly in the presence of Bcl-6 within germinal centers at day 7 and 14 after priming ([Fig. 3d](#F3){ref-type="fig"}). Toll-like receptor 4 (TLR4) agonist-based immunization used here promotes negligible IgM^+^ memory B cells with the majority of NP-specific memory B cells expressing IgG isotypes (not shown). Upon antigen re-challenge, NP-specific IgG2a^+^ memory B cells expressed elevated amounts of T-bet that remained high for at least 14 days after recall ([Fig. 3d](#F3){ref-type="fig"}, right). In the presence of Blimp-1, IgG2a^+^ plasma cells from all stages of the primary and memory response expressed low but detectable amounts of T-bet ([Fig. 3d](#F3){ref-type="fig"}, left). Thus, T-bet is expressed early upon initiation of IgG2a class switch and remains expressed at all stages of antigen-specific IgG2a^+^ memory B cell development and response *in vivo*.

T-bet activity in IgG2a memory B cells {#S5}
--------------------------------------

As evidence for T-bet activity in antigen-specific IgG2a^+^ CD38^hi^ memory B cells, transcription for a series of known T-bet target genes^[@R23]^ were elevated at day 5 of the memory response ([Fig. 4a](#F4){ref-type="fig"}, top). Differential expression of these target genes implies that T-bet enables separate functions in IgG2a^+^ memory B cells compared to naive B cells. Recent studies have shown that Bcl-6 can directly bind to T-bet and repress T-bet target gene expression in T cells^[@R24]^. To test whether something similar occurs in B cells, we assayed the same T-bet target genes in germinal center B cells that contain elevated Bcl-6 and found that expression of these targets was diminished ([Fig. 4a](#F4){ref-type="fig"}, bottom). Furthermore, Blimp-1 has been shown to directly antagonize T-bet expression^[@R25]^. Analysis of T-bet target genes in plasma cells that contain elevated Blimp-1 protein revealed reduced expression for most of the genes tested ([Fig. 4b](#F4){ref-type="fig"}). Although T-bet activity is present in IgG2a^+^ memory B cells, Bcl-6 and Blimp-1 expression significantly decreases this activity within IgG2a^+^ GC B cells and IgG2a^+^ plasma cells respectively.

T-bet protein is expressed broadly across most IgG2a^+^CD38^hi^ memory B cells with low but detectable amounts in IgG1^+^CD38^hi^ memory B cells ([Fig. 4c](#F4){ref-type="fig"}). At the single cell level, the majority IgG2a^+^CD38^hi^ memory B cells expressed intermediate amounts of T-bet mRNA with a minor fraction expressing substantially higher amounts per cell ([Fig. 4d](#F4){ref-type="fig"}). As suspected from the population analysis, many of the T-bet expressing memory cells also expressed detectable IFN-γ mRNA. Thus, it is likely that IgG2a^+^ memory B cells are a source of IFN-γ *in vivo*.

BCR-driven IgG2a response requires T-bet expression {#S6}
---------------------------------------------------

As IgM memory B cells were not actively excluded in previous experiments, we purified IgG2a^+^ B cells from unimmunized CreER^T2^ *Tbx21*^F/F^ mice and treated these cells with 4-OHT *in vitro*. These treated IgG2a^+^ memory B cells were transferred into *Rag1*^−/−^ recipients and reactivated through their BCR with anti-IgG2a. This *in vivo* stimulus induced robust production of IgG2a^+^ plasma cells with negligible numbers of CD19^+^ non-plasma cells remaining 4 days after transfer ([Fig. 5a](#F5){ref-type="fig"}). Nevertheless, after treatment with 4-OHT, there was a 75% reduction in IgG2a^+^ plasma cells with no increase in residual CD19^+^ B cell compartment. While cell recovery was low, similar trends were obtained in a second series of experiments after sorting NP-specific memory B cells from immunized CreER^T2^ *Tbx21*^F/F^ mice, 4-OHT treatment *in vitro*, transfer into *Rag1*^−/−^ recipients and antigen re-challenge ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Nevertheless, IgG2a-selective defects were seen in total class-switched B cells using this experimental design (data not shown). Thus, B cell intrinsic T-bet was required to permit IgG2a^+^ BCR-driven plasma cell differentiation *in vivo*.

STAT-1, survival and IgG2a BCR expression requires T-bet {#S7}
--------------------------------------------------------

To examine how T-bet exerted its impact on IgG2a B cell fate, we used IgG1^+^ and IgG2a^+^ memory B cells from wild-type or CreER^T2^ *Tbx21*^F/F^ mice for *in vitro* studies. Deletion of *Tbx21* using 4-OHT *in vitro* resulted in a significant loss of STAT1 transcription, the signal transducer of IFN-γ, selectively in IgG2a^+^ B cells and not IgG1^+^ B cells, on a per cell basis ([Fig. 5b](#F5){ref-type="fig"}, left). In the absence of T-bet, there was also a small but significant impact on cell survival in short-term cultures in the presence of BAFF with loss of IgG2a^+^ and increase of IgG1^+^ B cells ([Fig. 5b](#F5){ref-type="fig"}, middle). However, over the same period, there was \>75% loss of transcription for mature IgG2a^+^ BCR transcripts on a per cell basis ([Fig. 5b](#F5){ref-type="fig"}, right). Secondary cultures using anti-BCR coated plates induced significant numbers of B cell blasts over 48 h *in vitro* while IgG2a^+^ B cells remained small by forward scatter in the absence of T-bet ([Fig. 5c](#F5){ref-type="fig"}). Small live cells from both culture conditions were selected for quantitative PCR analysis of mature IgG2a^+^ BCR transcripts with exaggerated losses detected in the absence of T-bet ([Fig. 5c](#F5){ref-type="fig"}, right). Thus, in the absence of T-bet *in vitro* IgG2a^+^ BCR down-regulation and loss of STAT1 transcription were more pronounced than overall loss in IgG2a^+^ memory B cells.

Next, we investigated the IgG2a^+^ B cell compartment in an *N*-ethyl-*N*-nitrosourea (ENU)-generated animal strain with a phosphorylation defect that prevents nuclear translocation in STAT1 named Domino (Stat1^Dom/Dom^)^[@R26]^. While T-bet expression was decreased by 50%, there was almost complete loss of IgG2a^+^ B cells ([Fig. 5d](#F5){ref-type="fig"}) with a compensatory increase in IgG1^+^ B cells within these mice ([Fig. 5e](#F5){ref-type="fig"}, left). Both trends become exaggerated upon adoptive transfer into *Rag1*^−/−^ mice in a mixed peripheral chimera without immunization ([Fig. 5e](#F5){ref-type="fig"}, right). Thus, both T-bet expression and STAT-1 activation appear necessary for continued IgG2a BCR expression and/or IgG2a^+^ memory B cell survival *in vivo*.

Separable programs for IgA and IgG2a memory B cells {#S8}
---------------------------------------------------

IgA antibody plays a dominant role at mucosal surfaces, binding to a variety of innate immune cells, enhancing phagocytosis and triggering the local release of cytokines and inflammatory mediators^[@R27],[@R28]^. TGFβRII expression by B cells is required for IgA class switch^[@R9]^ with some evidence for T^H^17 cell involvement co-coordinating mucosal IgA responses^[@R29]^. Transcription factors in the Runx and Smad family have been shown to promote germline IgA transcripts towards IgA class switch^[@R8],[@R30]^. To contrast the transcriptional program of IgG2a^+^ and IgA^+^ memory B cells, we isolated isotype-switched (IgM^−^IgD^−^) CD38^+^ B cells (also CD19^+^CD138^−^B220^+^) that were largely Ki67^−^ (non-cycling) as quiescent memory B cell compartments ([Fig. 6a,b](#F6){ref-type="fig"} from spleen or Peyer's patches). IgG2a^+^ memory B cells differentially expressed IFN-γRI and IFN-γRII while IgA^+^ memory B cells differentially expressed IL17Rc andIL22Rα2 suggesting differential responsiveness to IL-17 and IL-22. Furthermore, while the TGFβR was expressed similarly in both memory subsets, increased TGFβ signaling intermediates of the Smad family members Smad2/3/4 and TGFβ associated adapter Daxx was increased in IgA^+^ memory B cells ([Fig. 6c](#F6){ref-type="fig"}). CXCR3 protein was differentially expressed by IgG2a^+^ memory B cells while most IgA^+^ memory B cells expressed high amounts of integrin α~4~β~7~ ([Fig. 6d](#F6){ref-type="fig"}). These data suggest that IgG2a and IgA memory B cells have separable growth factor requirements, signaling propensity and tissue homing potential ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}).

Survival and BCR expression in IgA memory requires RORα {#S9}
-------------------------------------------------------

Of the major transcription factors downstream from TGF-β and IL-17 signaling, RORα was highly expressed in IgA memory cells as compared to other memory and naïve B cells ([Fig. 7a](#F7){ref-type="fig"}). GATA-3, Foxp3 and RORγt were detectable at only low amounts in naive B cells, IgG1^+^, IgG2a^+^ and IgA^+^ memory B cells. Germline deletion of RORα in mice produces a complex phenotype with neurological defects and early fatality^[@R31]^. Hence, to probe the function of RORα in IgA memory B cells, we silenced expression in normal IgA^+^ B cells using targeted siRNA. Whole mesenteric lymph node and Peyer's patch cells were nucleofected with RORα siRNA, resulting in \~50% decrease in RORα mRNA after 4 days culture *in vitro* ([Fig. 7b](#F7){ref-type="fig"}, left). This level of RORα knockdown resulted in \~50% decrease in mature IgA mRNA in the total cell population ([Fig. 7c](#F7){ref-type="fig"}, middle left). Isolating IgA^+^ memory B cells from these cultures revealed a \>80% reduction of mature IgA BCR transcripts on a per cell basis ([Fig. 7b](#F7){ref-type="fig"}, right). Thus, RORα is differentially expressed in IgA^+^ B cells with evidence for control of dynamic BCR expression.

To interfere with ROR protein function, we used the compound SR1001 recently described to inhibit RORα and RORγt transcriptional activity^[@R32]^. The presence of this functional inhibitor selectively decreased the number of IgA^+^ memory B cells that survived in culture for 6 days without impacting IgG1^+^ B cells ([Fig. 7c](#F7){ref-type="fig"}). To establish the influence of the inhibitor on IgA^+^ memory B cells, we treated purified IgA^+^ memory B cells with SR1001 over short-term cultures. As the drug only inhibits protein function, there was no significant impact on RORα mRNA expression ([Fig. 7d](#F7){ref-type="fig"}, right). However, there was a significant decrease in transcription of some known RORα targets, *Itpr1* and *Hif1a*. Interestingly, there were significant decreases in the abundance of mature IgA BCR transcripts per cell ([Fig. 7d](#F7){ref-type="fig"}, left). Thus, RORα can impact IgA^+^ memory B cell function with evidence that it is required for IgA^+^ B cell survival and control of IgA BCR mRNA transcription.

DISCUSSION {#S10}
==========

Antigen-specific B cell memory is central to long-term immune protection and develops across many different antibody classes. Here, we focus on unique properties of IgG2a^+^ and IgA^+^ memory B cells to demonstrate that divergent transcriptional regulators maintain class-specific memory B cell subset integrity. Both T-bet and RORα regulate mature BCR transcription, which appears necessary for memory B cell survival in IgG2a^+^ and IgA^+^ memory B cells respectively. In addition, our study utilizes conditional genetic models that temporally delete T-bet to demonstrate severe defects in the capacity of IgG2a^+^ memory B cells to respond to antigen. Both IgG2a^+^ and IgA^+^ memory B cells expressed different transcriptional programs that reflect separate potentials in cytokine secretion, trafficking and survival that permit flexibility in long-term antigen-specific immune protection. We propose that the events that lead to class-switch after antigen-experience lead to the imprinting of molecular programs whose persistence is essential for maintaining memory B cell subset identity.

The dynamic regulation of BCR transcription was a common component of both RORα and T-bet programs. We found consensus binding sites for both transcription factors within the immunoglobulin 3\' regulatory region known to control class switch and antibody secretion^[@R33]^. Thus, separable T-bet and RORα dependent transcriptional programs within IgG2a^+^ and IgA^+^ memory B cells also control the central recognition properties of antigen-specific B cell memory.

Cognate T~FH~ cells regulate multiple facets of antigen-specific memory B cell development^[@R4]^. Bcl-6 programs T~FH~ development and movement to B cell areas for cognate control of B cell immunity^[@R34]^. Cytokine production occurs in these follicular regions upon contact with antigen-primed B cells in ways that can initiate antibody class-switch^[@R35]^. Within germinal centers, T~FH~ cell contact^[@R36]^ regulates the clonal composition of germinal center B cells and export into B cell memory compartments^[@R37]^. In germinal center B cells, Bcl-6 can antagonize T-bet function and this dynamic molecular interplay may underpin germinal center B cell fate and IgG2a^+^ memory B cell development. There is evidence for cytokine-producing germinal center T~FH~ cells that engage germinal center B cells in an antibody class-specific manner^[@R35]^. In this scenario, antibody class-specific regulation by cognate T~FH~ cells may streamline affinity maturation and efficiently promote memory B cell development.

T-bet regulates critical cellular functions within IgG2a^+^ memory B cells. In naïve T cells, signaling through the antigen receptor synergizes with IFN-γ--induced STAT1 activation to promote initial T-bet expression^[@R12]^. We demonstrate a similar IFN-γ, STAT1 and T-bet dependent regulatory axis in IgG2a^+^ memory B cells. Ablating T-bet expression interferes with this program, resulting in down-regulation of BCR transcription and loss of IgG2a^+^ memory B cells. While antigen binding by memory BCR is not required for survival^[@R38]^, we propose that memory B cells rely on tonic signals through BCR for survival as found in naïve B cells^[@R39]^. Similar to antigen-specific plasma cells^[@R20]^, memory B cells may also retain antigen-presenting capacity for extended periods *in vivo*. In this manner, continued BCR expression may also indirectly permit ongoing local contact with antigen-specific T~FH~ cells^[@R40]^.

T-bet activity establishes a molecular framework that governs IgG2a B cell functions. While T-bet binds to target promoters regardless of cell type, its ability to transactivate and remodel loci is cell context-dependent^[@R23]^. The regulation of genes by T-bet is also coupled to the dynamic expression of its molecular antagonists Bcl-6 and Blimp-1 (refs.^[@R24],\ [@R25]^). Interestingly, T-bet can assort asymmetrically in T cells at cell division^[@R41]^ and more recently Bcl-6 was shown to assorted unevenly across GC B cells^[@R42]^. Our studies show that the co-expression of Bcl-6 with T-bet in GC B cells results in repression of transcription of T-bet targets. However, rather than abolishing a T-bet-defined subset, Bcl-6 transiently and reversibly alters IgG2a^+^ programming to allow productive GC activity and IgG2a^+^ memory B cell development.

RORαlike T-bet, is able to recruit chromatin remodeling machinery and directly transactivate loci^[@R11]^. However, unlike T-bet, the interactions of RORα with Bcl-6 and Blimp-1 have not been characterized. Although some studies point to Bcl-6 as repressing RORγt and T~H~17 differentiation^[@R43],[@R44]^, the cell-intrinsic effects on RORα is unknown. Mice deficient in RORα have severe defects and die early due to the early expression of RORα during development^[@R11]^. Studies on RORα targets in immune cells provide connections to activation of IL-17, IL-17F, IL-22, and IL-23R^[@R45]^, and in repression of IL-6 and tumor necrosis factor^[@R46]^. It is unknown whether activation of these targets is direct or indirect, and we found no differential expression of these targets in IgA^+^ memory B cells (not shown). However, RORα is involved in several other pathways including calcium signaling, circadian rhythm and cellular metabolism^[@R11]^ with evidence for an impact of the SR1001 on Iptr1 and HIF-1α that might indicate other pathways in which IgA^+^ memory B cells may be unique from other classes.

Antigen-specific memory B cell responses may also require sub-specialized regulatory programs organized by antibody class. Upon antigen re-challenge, memory B cells require cognate T cell help to expand and differentiate into plasma cells^[@R47]^. IgM memory B cells express separable functions and capacity to respond compared to their IgG counterparts^[@R3],[@R48]^. Expression of downstream antibody classes engage different signaling pathways based on the constant region of the BCR^[@R5],[@R6]^. Other class-specific memory B cell properties control migration, such as T-bet driving IgG2a^+^ memory B cells to inflammatory sites via CXCR3 expression and α~4~β~7~ integrin guiding IgA^+^ memory cells to mucosal tissues^[@R27]^. Enhanced STAT1 and IFN-γR transcription may uniquely sensitize IgG2a^+^ memory B cells to IFN-γ signals. Similarly, RORα can enhance calcium sensitivity within cells^[@R49]^ and CamKIV can enhance RORα expression^[@R50]^. These types of changes in IgA^+^ memory B cells may lower BCR activation thresholds in a class-specific manner. Therefore, multiple attributes of class-specific B cell memory that are introduced upon development may be further reinforced upon antigen recall under the cognate guidance of memory T~FH~ cells^[@R40]^.

Memory B cells are generally considered functionally equivalent, differing only by the antibody isotype they express. In the current study, we reveal unexpectedly that B cell memory is organized in class-specific subsets each with separate central transcriptional regulators. Specifically, transcriptional regulators T-bet and RORα control divergent IgG2a and IgA memory B cell subsets respectively to control separate functions within these unique class-specific memory B cell compartments. T-bet is used by many cell types in response to inflammatory stimuli with focus on the clearance of intracellular pathogen^[@R12]^. We now reveal that IgG2a^+^ B cell memory also relies selectively on a T-bet dependent program to establish and maintain subset integrity. Similarly, IgA^+^ B cell memory is specialized to protect the mucosal surfaces^[@R27]^ and the selective use of transcriptional regulator RORα enhances this unique memory B cell function. Importantly, these unique developmental programs can be exploited for directed immunotherapeutic applications, future class-skewing vaccine formations and the treatment of cancer and autoimmunity.

METHODS {#S11}
=======

Animals {#S12}
-------

Tbx21^−/−^ (purchased from Jackson), C57BL/6 (B6), Rag1^−/−^, B6.CD45.1, Tbx21^F/F^, STAT1^Dom/Dom^ and Tbx21F/F;Rosa26-CreER^T2^ were housed in pathogen-free conditions. All experiments were performed in compliance with federal laws and institutional guidelines as approved by the Scripps Research Institutional Animal Care and Use Committee. We generated Rosa26-CreER^T2^;Tbx21^F/F^ by crossing Tbx21^F/F^ mice with Rosa26-CreER^T2^ mice (purchased from Jackson). For genotyping of mutants, the following primers were used at 0.4µM final concentration in a standard FastStart Reaction Mix (Roche) using manufacturer's guidelines: oIMR1719 (Common) (5\'-TGGGCATACAGGAGGCAGCAACAAATA-3 \'), oIMR1718 (Wild-Type) (5\'-GACTGAAGCCCCGACCCCCACTCCTAAG-3\'), oIMR1717 (Mutant) (5\'-GCGCGAAGGGGCCACCAAAGAACGGAG-3\') for genotyping of B6.129S6-*Tbx21^tm1Glm^*/J (Tbx21^−/−^). oIMR8545 (common) (5\'-AAAGTCGCTCTGAGTTGTTAT-3\'), oIMR8546 (wild-type reverse) (5\'-GGAGCGGGAGAAATGGATATG-3\'), oIMR8547 (mutant reverse) (5\'-CCTGATCCTGGCAATTTC G-3\') were used for genotyping of B6.129-*Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj^*/J (Rosa26-CreER^T2^) mice. For the detection of non-excised locus in Tbx21^F/F^ animals and cells primers A (sense) (5\' -- TATGATTACACTGCAGCTGTCTTC AG-3\') and B (anti-sense) (5\'-CAGGAATGGGAACATTCGCCTGTG-3\') were used and for detection deletion within locus deltaF (sense) (5\'-AGCCATCTCTCCAGCCTA CA-3\') and C2 (anti-sense) (5\'-CTCTGCCTCCCATCTCTTAGGAGC-3\') were used for amplification.

### Flow Cytometry {#S13}

Draining lymph nodes and spleen were removed from unimmunized or immunized animals and single cell suspensions in PBS with 5% (vol/vol) FBS prepared. 4 × 108 cells per mL were incubated for 15 min with anti-CD16/32 (Fc block, 2.4G2) followed for 45 min at 4°C with fluorophore-labeled or biotin-labeled monoclonal antibodies: allophycocyanin-conjugated anti-CD138 (281-2), allophycocyanin-Cy7-conjugated anti-CD19 (1D3), phycoerythrin-conjugated anti-CD138 (281-2), phycoerythrin texas red-conjugated anti-B220 (RA3-6B2), fluorescein isothiocyanate-conjugated anti-IgG1 (A85-1), anti-IgG3 (R40-8L), Horizon V500-conjugated anti-CD8 (53-6.7) and anti-CD4 (Rm4-5), biotin-conjugated anti IgG2ab (5.7) \[all from BD Biosciences\]. Phycoerythrin-conjugated anti-T-bet (eBio4B10), Phycoerythrin-cy7-conjugated anti-CD45.1 (A20), Phycoerythrin-cy7-conjugated anti-CXCR3 (CXCR3-173), fluorescein isothiocyanateconjugated anti-CD45.2 (104), Biotin-conjugated anti-IgG2b (RMG2b-1), Biotin-conjugated anti-CD45.2 (104), and Biotin-conjugated anti-IgA (RMA-1) \[all from Biolegend, Inc\]. Alexa Fluor 700-conjugated anti-CD38 (90), phycoerythrin-cy5-conjugated anti-Gr-1 (Ly6G/C, RB68C5) \[all from eBiosciences, Inc\]. Allophycocyanin-conjugated anti-NP, phycoerythrin-conjugated NP, peridinin-chlorophyll protein-cy5.5-conjugated anti-IgM (331.12), Pacific Blue-conjugated IgD (11.26) \[all from MMW Lab\]. Immunoglobulin-specific antibodies were added in a separate step for 45 min at 4°C with normal mouse serum (1:50) before other reagents were added. Streptavidin-conjugated Qdot 655 (Invitrogen) were used as a second step visualization reagent. For intracellular staining, cells were fixed, permeabilized, and stained using the protocol in the Foxp3 Staining Buffer Set (eBioscience). Cells were washed and re-suspended in PBS/FBS and analyzed with a FACSAria III with FACSDiva software (BD Biosciences). Data were analyzed with FlowJo software (Tree Star, Inc).

### Quantitative PCR {#S14}

cDNA was prepared as described previously ([@R51]). Briefly, 5000 cells were sorted directly into lysis buffer (Qiagen) and mRNA was purified using RNeasy Kit (Qiagen). cDNA was generated using the First-Strand Synthesis System for RT-PCR (Invitrogen) using random hexamers. SYBR Green qPCR was conducted using the Platinum SYBR Green Supermix UDG reaction mix (Invitrogen) on the StepOnePlus Real-time PCR system and analyzed using the Step One Software (Applied Biosystems). Primers were used at a final concentration of 0.25µM and can be found in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. GAPDH was used as an endogenous control. For measurement of T-bet expression levels, naïve B cells were assigned a value of 1, and the relative expression assigned accordingly. For measurement of STAT1 and IgG2a post-switch mRNA levels, cells receiving 4-OHT treatment were assigned a value of 1, and the relative expression assigned accordingly. For cells treated with RORa siRNA or SR1001, cells receiving the drug or siRNA were assigned a value of 1, and the relative expression assigned accordingly. For single cell qPCR on mRNA, single cells were directly sorted into 2× Reaction buffer containing SSIII RT Platinum Taq found in the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase Kit (Invitrogen) and containing outside primers for IFNg, T-bet, and GAPDH at a final concentration of 0.25µM. 96-well plates were placed in PCR cycler for 15 minutes at 50C, followed by 2 minutes at 95C. 22 cycles of 15 seconds at 95C followed by 4 minutes at 60C were then performed. 1µL of product was used in a standard qPCR reaction described above.

Adoptive transfers {#S15}
------------------

Draining lymph nodes and spleen were removed from unimmunized or immunized animals and single cell suspensions in PBS. For germline knockout peripheral chimeras, 3.5×10^7^ cells from Tbx21^−/−^ or STAT1^Dom/Dom^ and B6.CD45.1 mice where mixed 1:1 (7×10^7^ cells total) and injected intraperitoneally (i.p.) into Rag1^−/−^ hosts. Mice were then immunized subcutaneously at the base of tail with 400µg NP-KLH in MPL-based adjuvant. For conditional knockout peripheral chimeras, splenocytes from Rosa26-CreER^T2^;Tbx21^F/F^, Rosa26-CreER^T2^;Tbx21^+/+^, and B6.CD45.1 were treated with 4-hydroxytamoxifen (4-OHT) (Sigma). In brief, 1×10^7^ from Rosa26-CreER^T2^;Tbx21^F/F^ or Rosa26-CreER^T2^;Tbx21^+/+^ unfractionated splenocytes were treated 1 hour in 4-OHT-containing media (RPMI, 10% FBS, 2mM L-gluatmine, and 1µM 4-OHT), filtered, and mixed 1:1 with 1×10^7^ cells from B6.CD45.1 mice (2×10^7^ total) and transferred i.p. into Rag1^−/−^ hosts. Mice were immunized 1 day later with 400µg NP-KLH in PBS. For experiments with depletion of plasma cells and naïve B cells, cells were FACS-purified and 1×10^6^ cells from Rosa26-CreER^T2^;Tbx21^F/F^ mice were treated with 4-OHT or vehicle for 1 hour and transferred i.p. into Rag1^−/−^ hosts. For IgG2a^+^ B cell transfers, cells were FACS-purified and 1×10^4^ cells from Rosa26-CreER^T2^;Tbx21^F/F^ mice were treated with 4-OHT or vehicle for 1 hour and transferred i.p. into Rag1^−/−^ hosts. Mice were given 75µg anti-IgG2a antibody (R19-15, BD Biosciences) i.p. 1 day after transfer into empty hosts.

Immunizations {#S16}
-------------

Mice were immunized subcutaneously at the base of the tail with 400µg 4-hydroxy-3-nitrophenylacetyl (Biosearch) conjugated to keyhole limpet hemocyanin (Pierce, NP-KLH) in monophosphoryl lipid A-based adjuvant supplemented with trehalose dimycolate (1mg per 1mg MPL, Sigma). Antigen re-challenge was done 120 days or more after priming with 400 µg NP-KLH in MPL-based adjuvant. Soluble boost was done by mixing 400 µg NP-KLH in PBS.

4-Hydroxytamoxifen treatment of mice {#S17}
------------------------------------

4-hydroxytamoxifen (4-OHT) was dissolved in 100% ETOH at a final concentration of 20mg/mL, and was injected intraperitoneally (i.p) into unimmunized Rosa26-CreER^T2^ or Tbx21F/F;Rosa26-CreER^T2^ mice at a dose of 0.5mg/mouse for the first injection, and 0.25mg/mL for the 2 subsequent injections.

Cell culture {#S18}
------------

IgG2a^+^ or IgG1^+^ cells were FACS-purified with a FACSAria III. For survival studies, 8×10^3^ cells were placed in media (DMEM, 10% FBS, 2mM L-gluatmine, and 1µM 4-OHT) and given 200ng/mL BAFF (R&D systems) for 48 hours and total numbers were analyzed with a FACSAria III. For gene expression analysis, 2×10^4^ cells were placed in media (DMEM, 10% FBS, 2mM L-gluatmine, 50µM beta-mercaptoethanol and 1µM 4-OHT) and given 200ng/mL BAFF (R&D systems) for 48 hours and live (PI^−^) cells were sorted directly into lysis buffer and processed as stated above. For BCR-stimulation studies, 2×10^4^ cells were placed in media (DMEM, 10% FBS, 2mM L-gluatmine, and 1µM 4-OHT) and given 200ng/mL BAFF (R&D systems) for 48 hours, and then transferred into plates coated overnight at 4°C with biotin-conjugated anti-IgG2a^b^ (5.7) \[BD Biosciences\] or biotin-conjugated anti-IgG1 (RMG1-1) \[Biolegend, Inc\], and supplemented with a further 200ng/mL of BAFF. Live (PI^−^) cells were sorted directly into lysis buffer 48 hours after transfer to coated plates and processed as stated above for gene expression analysis

SiRNA {#S19}
-----

For siRNA experiments, Peyer's Patches and mesenteric lymph nodes were homogenized in media (DMEM, 10% FBS, 2mM L-glutamine, 50µM beta-mercaptoethanol) from unimmunized C57BL/6 animals. 3×10^6^ cells were nucleofected using the Amaxa Mouse B cell Nucleofector Kit (Lonza) according to manufacterer's protocol. Each well was nucleofected with 300pmol of either Silencer Select Pre-designed siRNA against RORα (Ambion) or a scrambled control. Cells were collected whole or sorted to purity 4 days after nucleofection, and mRNA was isolated as above.

SR1001 Treatment {#S20}
----------------

SR1001 was dissolved in 10% DMSO, 10% Tween-80, and 80% water. Whole splenocytes were homogenized and 2×10^7^ cells were treated with 5µM SR1001 for 6 days in media (DMEM, 10% FBS, 2mM L-glutamine, 50µM beta-mercaptoethanol). For IgA memory cultures, Peyer's Patches and mesenteric lymph nodes were homogenized and IgA memory cells were FACS-purified and placed into culture with media and 5µM SR1001 for 24 hours. Live cells were collected and mRNA was obtained and analyzed as above.

Statistics {#S21}
----------

Mean values, standard error of the mean, Student's T-test, and Mann-Whitney test were calculated with GraphPad Prism (GraphPad Software). A *P* value \<0.05 was considered to be statistically significant (\*\<0.05, \*\*\<0.01, \*\*\*\<0.001).
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![B cell intrinsic T-bet is required for IgG2a formation\
**(a)** Total numbers of polyclonal splenic B cells (Gr1^−^CD4^−^CD8^−^, CD19^+^ or CD138^+^) that are switched (IgM^−^IgD^−^) and CD138^−^ B220^hi^. C57BL/6 (WT, grey bars) or Tbx21^−/−^ mice (KO, black bars). Mean±sem; n=5 \*\*P\<0.01. **(b)** Rag1^−/−^ mice receive 1:1 mixture of splenocytes from CD45.1 (WT) and Tbx21^−/−^ (KO) donors and immediately immunized with NP-KLH in adjuvant. Frequency boxed in FACS profile (left panel) and total cell numbers (right panel) of B cells (Gr1^−^CD4^−^CD8^−^, CD19^+^ or CD138^+^) from donors transferred into Rag1^−/−^ recipients. **(c)** Day 21 splenic NP-specific response of Rag1^−/−^ recipient mice from adoptively transferred and immunized cells in (b). Boxed area indicates frequency (left panels) of switched (IgM^−^) B cells (Gr1^−^CD4^−^CD8^−^ and CD19^+^ or CD138^+^). Total number (right panel) of NP-specific cells prior to transfer (0), with adjuvant only (adj), or in WT or KO compartments immunized with NP-KLH in adjuvant. **(d)** Class-specific frequencies and total cell number of NP-specific switched B220^hi^ B cells. Frequencies represent percentage of same congenic compartment (left panels) and total numbers (right panels) following transfer and immunization in (b). **(e)** Class-specific frequencies and total cell number of NP-specific plasma cells (Gr1^−^CD4^−^CD8^−^, IgM^−^IgD^−^, NP^+^CD138^+^), that are switched. Frequencies (boxed in left panels) and total numbers (right panels) following transfer and immunization in (b). (b--e), Mean±sem; n=5 Rag1^−/−^ mice.\*P\<0.05,\*\*P\<0.01.](nihms366887f1){#F1}

![T-bet is required for memory B cell survival and function in vivo\
**(a)** Mice received daily injections of 4-OHT for 3 days and spleens were harvested on day 4. T-bet expression in total splenocytes (left panel) following a forward and side scatter lymphocyte gate. Total cell numbers of T-bet^+^ splenocytes (middle panel) or IgG2a^+^ and IgG1^+^ B cells following *in vivo* 4-OHT treatment in Rosa26-CreER^T2^;Tbx21^+/+^(WT) or Tbx21^F/F^(F/F) mice (right panel). **(b)** T-bet expression in B220^hi^CD38^+^IgG2a^+^ B cells (Gr1^−^CD4^−^CD8^−^ IgM^−^IgD^−^ CD19^+^CD138^−^) (white) or naïve B cells (Gr1^−^CD4^−^CD8^−^ IgM^+^IgD^+^ CD19^+^B220^+^) (grey). (a--b), Mean±sem; n=3 WT or F/F mice, \*P\<0.05, **(c)** Splenic NP gate from B cells (Gr1^−^CD4^−^CD8^−^, CD19^+^ or CD138^+^) that are IgM^−^ and transferred into Rag1^−/−^ recipients. **(d)** 7 days after transfer in (c) and soluble boost with NP-KLH (right panels). Expression of CD138 and B220 on NP-specific cells following transfer and soluble boost. Total B220^hi^ B cell numbers (right panel). **(e)** Frequency of IgG2a^+^ and IgG1^+^ NP-specific B cells (left panels) and total cell numbers (right panel) after transfer and soluble boost gated on B220^hi^ in (c). **(f)** Total cell numbers of NP-specific plasma cells (CD138^+^) from transfer in (c). (c--f) Mean±sem; n=5 Rag1^−/−^ mice. \*P\<0.05,\*\*P\<0.01.](nihms366887f2){#F2}

![T-bet expression during antigen-specific IgG2a memory development\
**(a)** Day 7 NP-specific B cell response in lymph nodes of C57BL/6 mice immunized with adjuvant only or adjuvant with NP-KLH gated Gr1^−^CD4^−^CD8^−^, B cell positive \[CD138^+^ or CD19^+^\] and IgM- (left panels). Timecourse of total NP-specific B cells (right panel). (**b**) Day 7 representative NP-specific B cell subsets (left panel) and B220^hi^ expression of CD38^+^ and IgG2a^+^ (right panel). (**c**) mRNA for Bcl6 (left panel) or Prdm1 (right panel) after isolation of naïve (N)(day 0, IgM^+^IgD^+^CD23^+^) and NP-specific CD19^+^B220^hi^IgG2a^+^ day 7 pre-GC (CD38^+^), day 7 GC (CD38^−^), day 14 GC (CD38^−^), day 14 memory (M)(CD38^+^), recall day 5 and 14 memory cells (CD38^+^). mRNA for Prdm1 (right panel) after isolation of IgG2a^+^ plasma cells (CD138^+^) (**d**) T-bet expression for T~H~ cell samples (antigen-responsive T~FH~ cells) and populations described in (c) (left panel) and for IgG2a^+^ plasma cells (CD138^+^, right panel). Mean±sem; n≥5 mice.](nihms366887f3){#F3}

![Evidence for T-bet activity in IgG2a^+^ memory B cells\
**(a)** mRNA for T-bet targets at recall day 5 IgG2a^+^ memory versus naive B cells from day 5 memory NP-specific B cells from draining lymph nodes of C57BL/6 mice immunized with adjuvant and NP-KLH are FACS-purified and gated on Gr1^−^CD4^−^CD8^−^, B cell positive \[CD138^+^ or CD19^+^\], switched (IgM^−^IgD^−^), and NP^+^IgG2a^+^ memory B220^hi^CD38^+^CD138^−^. Naïve B cells are FACS-purified and gated on Gr1^−^CD4^−^CD8^−^, B cell positive (B220^+^CD19^+^CD138^−^) and IgM^+^IgD^+^CD23^+^ (top panel). IgG2a^+^ day 14 mature-GC (CD38^−^) versus recall day 5 (bottom panel). Mean±sem, n≥5. **(b)** mRNA for T-bet targets in recall day 5 IgG2a^+^ memory versus IgG2a^+^ plasma cells. NP^+^IgG2a^+^ plasma cells FACS-purified by gating on Gr1^−^CD4^−^CD8^−^, B cell positive \[CD138^+^ or CD19^+^\], switched (IgM^−^IgD^−^) and CD138^+^ are compared to recall day 5 IgG2a^+^ memory FACS-purified as in (a). **(c)** T-bet MFI in IgG2a^+^(G2a) and IgG1^+^(G1) B220^hi^CD38^+^ B cells (Gr1^−^CD4^−^CD8^−^ IgM^−^IgD^−^ CD19^+^CD138^−^) with control histograms from Tbx21^−/−^ mice in grey. **(d)** T-bet and IFN-γ mRNA expression from single FACS-sorted cells (left panel) that are Gr1^−^CD4^−^CD8^−^, B cell positive \[CD19^+^or CD138^+^\], switched IgM^−^IgD^−^, and B220^hi^CD138^−^CD38^+^IgG2a^+^. Frequency of total single cells shown in left panel positive for T-bet or IFN-γ signal (right panel).](nihms366887f4){#F4}

![B cell intrinsic T-bet is required for survival, IgG2a^+^ BCR expression and function\
**(a)** Class-switched memory B cells (GR1^−^CD4^−^CD8^−^ IgM^−^IgD^−^CD19^+^B220^+^CD138^−^CD38^+^) were FACS-purified from spleens of unimmunized Tbx21^F/F^; Rosa26-CreER^T2^ mice treated ex vivo with 4-OHT and transferred into Rag1^−/−^ recipients. 1 day after transfer, mice were injected with anti-IgG2a antibody and spleens collected 3 days after injection. Frequency and total cell number of IgG2a^+^ plasma cells (GR1^−^CD4^−^CD8^−^CD138^+^) from unimmunized Tbx21^F/F^;Rosa26-CreER^T2^ mice after transfer into Rag1^−/−^ mice following donor cell treatment with 4-OHT or vehicle (on CD4^−^CD8^−^CD138^−^). Mean±sem; n=3 Rag1^−/−^ mice. \*P\<0.05 **(b)** Total cell number and mRNA expression from live PI^−^ FACS-purified Gr1^−^CD4^−^CD8^−^, B cell positive \[CD19^+^orCD138^+^\], switched IgM^−^IgD^−^, and class-specific CD138^−^B220^hi^CD38^+^ B cells from unimmunized Rosa26-CreER^T2^ Tbx21^+/+^(WT) or Tbx21^F/F^(F/F) mice treated with 4-OHT (n≥3) after 2 days. Forward scatter of PI^−^ cells sorted after 2 days for mRNA analysis from wells containing Rosa26-CreER^T2^ Tbx21^+/+^(WT) or Tbx21^F/F^(F/F) cells. mRNA expression is displayed as F/F\'s percentage relative to WT (%) \*P\<0.05 **(c)** Total cell number and mRNA expression from IgG2a^+^ memory B cells sorted as in (b) after 4 days. Cells were re-activated with anti-IgG2a antibody after 48 hours in culture. Forward scatter of total PI^−^ cells and total number of PI^−^ blasting cells from wells containing Rosa26-CreER^T2^ Tbx21^+/+^(WT) or Tbx21^F/F^ (F/F) cells (left panels). Forward scatter of actual PI^−^ cells sorted for mRNA analysis from wells containing Rosa26-CreER^T2^ Tbx21^+/+^(WT) or Tbx21^F/F^(F/F) cells (right panels). \*P\<0.05 **(d)** T-bet expression in splenic switched B220^hi^CD38^+^IgG2a^+^ B cells from wild-type mice (C57BL/6), STAT1^Dom/Dom^ and Tbx21^−/−^ mice on the C57BL/6 background. **(e)** Frequency of IgG2a^+^ and IgG1^+^ B220^hi^CD38^+^ B cells before (left panel) and 21 days following generation of peripheral chimeras (right panel). Mean±sem; n≥5 Rag1^−/−^ mice. \*P\<0.05, \*\*P\<0.01.](nihms366887f5){#F5}

![Separable programs for IgG2a^+^ and IgA^+^ memory B cells\
**(a)** Frequency of Gr1^−^CD4^−^CD8^−^, B cell positive \[CD19^+^orCD138^+^\], switched IgM^−^IgD^−^, class-specific CD138^−^B220^hi^ B cells in unimmunized C57BL/6 mice. Representative staining from spleen (left panel) and Peyers Patches (right panel) **(b)** Ki67 staining on cells from (a). Shaded histograms are from CD38^+^ (memory) cells gated as in (a), and white histograms are CD38^−^ (GC) cells gated as in (a). **(c)** mRNA expression of IgG2a^+^ or IgA^+^ splenic B cells (a) for cytokine receptors (left panel) or signal transduction molecules (right panel). **(d)** Surface staining (MFI) of IgG2a^+^, IgG1^+^, IgA^+^ or naive splenic B cells for CXCR3 (left panels) and α4β7 (right panel). (a--d) Mean±sem; n≥4 mice. \*\*\*P\<0.001.](nihms366887f6){#F6}

![RORα regulates survival and BCR expression in IgA^+^ Memory B cells\
**(a)** mRNA expression for indicated gene products relative to naive B cells from IgG2a^+^, IgG1^+^, or IgA^+^ cells gated on Gr1^−^CD4^−^CD8^−^, B cell positive \[CD19^+^orCD138^+^\], switched IgM^−^IgD^−^, class-specific CD38^+^B220^hi^CD138^−^ B cells in unimmunized C57BL/6 mice. (**b**) mRNA from pooled Peyer's Patches and mesenteric lymph nodes 4 days after nucleofection with a Rorα-specific (Rorα) (shown in black) or control (Ctrl) (shown in grey) siRNA in samples from total cells (left panels) or from sorted IgA^+^CD38^+^B220^hi^ switched B cells (right panels). mRNA expression is displayed as F/F\'s percentage relative to WT (%) **(c)** Frequency and total number of class-specific CD38^+^B220^hi^ splenocytes after treatment with 5µM SR1001 or vehicle for 6 days. **(d)** mRNA for indicated gene products from FACS-purified CD38^+^IgA^+^ cells from (a) treated with 5µM SR1001 (black bars) or vehicle (grey bars) for 24 hours. Mean±sem; n≥4; \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.](nihms366887f7){#F7}
